Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients

Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline characteristics. Data on treating HCV GT4 with LDV/...

Full description

Bibliographic Details
Main Authors: Mohammed A Babatin, Abdullah S AlGhamdi, Abdullah M Assiri, Haziz AlBiladi, Hammad S AlOthmani, Mohammed H Mogharbel, Wedad Mahallawi, Tarik Asselah, Faisal M Sanai
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:The Saudi Journal of Gastroenterology
Subjects:
Duration
genotype 4
hepatitis C
ledipasvir
sofosbuvir
Online Access:http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2019;volume=25;issue=1;spage=55;epage=60;aulast=Babatin

Internet

http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2019;volume=25;issue=1;spage=55;epage=60;aulast=Babatin

Similar Items